Saturday, June 16, 2012

Research on Convergence Insufficiency

 It is important that we know and understand this research for our patients' benefit. This research clearly shows that in-office optometric vision therapy is the most efficacious treatment for convergence insufficiency. Major insurance companies are denying in-office vision therapy unless you conduct out of office/home therapy first. This rational for the patient having 12 out of office vision/home based therapy sessions before in office therapy is inappropriate, unsubstantiated by research and potentially harmful to our patient's well being and quality of life.They are recommending the least effective, most time consuming, and costly methodology of treatment. I respectfully request that these insurance companies reconsider this ill advised policy immediately. 

If you are a patient reading this, go to your employer and ask them to support vision therapy by telling your insurance company to do no harm, to waste no money, and to support treatments shown to be effective. DM

Borsting E, Mitchell GL, Kulp MT, Scheiman M, Amster DM, Cotter S, Coulter RA, Fecho G, Gallaway MF, Granet D, Hertle R, Rodena J, Yamada T; CITT Study Group.
Optom Vis Sci. 2012 Jan;89(1):12-8.

Scheiman M, Cotter S, Kulp MT, Mitchell GL, Cooper J, Gallaway M, Hopkins KB, Bartuccio M, Chung I; Convergence Insufficiency Treatment Trial Study Group.
Optom Vis Sci. 2011 Nov;88(11):1343-52.

Scheiman M.
J AAPOS. 2011 Apr;15(2):123-4. No abstract available.

Scheiman M, Gwiazda J, Li T.
Cochrane Database Syst Rev. 2011 Mar 16;(3):CD006768. Review.

Scheiman M, Kulp MT, Cotter S, Mitchell GL, Gallaway M, Boas M, Coulter R, Hopkins K, Tamkins S; Convergence Insufficiency Treatment Trial Study Group.
Optom Vis Sci. 2010 Aug;87(8):593-603.

Cotter S, Kulp M, Scheiman M, Hertle R, Mitchell GL, Rouse M; Convergence Insufficiency Treatment Trial Executive Committee.
Arch Ophthalmol. 2009 Sep;127(9):1229-30; author reply 1230-1. No abstract available.

Rouse M, Borsting E, Mitchell GL, Kulp MT, Scheiman M, Amster D, Coulter R, Fecho G, Gallaway M; CITT Study Group.
Optom Vis Sci. 2009 Oct;86(10):1169-77.

Convergence Insufficiency Treatment Trial Study Group.
Optom Vis Sci. 2009 Sep;86(9):1096-103.

Scheiman M, Rouse M, Kulp MT, Cotter S, Hertle R, Mitchell GL.
Optom Vis Sci. 2009 May;86(5):420-8.

Rouse M, Borsting E, Mitchell GL, Cotter SA, Kulp M, Scheiman M, Barnhardt C, Bade A, Yamada T; Convergence Insufficiency Treatment Trial (CITT) Investigator Group.
Optom Vis Sci. 2009 Apr;86(4):357-63. Erratum in: Optom Vis Sci. 2009 Jun;86(6):786. Yamada, Tomohike [corrected to Yamada, Tomohiko].
Kulp M, Mitchell GL, Borsting E, Scheiman M, Cotter S, Rouse M, Tamkins S, Mohney BG, Toole A, Reuter K; Convergence Insufficiency Treatment Trial Study Group.
Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2560-6. Epub 2009 Jan 17.

Kulp MT, Borsting E, Mitchell GL, Scheiman M, Cotter S, Cooper J, Rouse M, London R, Wensveen J; Convergence Insufficiency Treatment Trial (CITT) Investigator Group.
Optom Vis Sci. 2008 Apr;85(4):255-61.

Convergence Insufficiency Treatment Trial (CITT) Study Group.
Ophthalmic Epidemiol. 2008 Jan-Feb;15(1):24-36.Free PMC Article

Scheiman M, Mitchell GL, Cotter S, Rouse M, Borsting E, Kulp M, Cooper J, London R, Wensveen J; Convergence Insufficiency Treatment Trial (CITT) Study Group.
Optom Vis Sci. 2006 Nov;83(11):857-8; author reply 858-9. No abstract available.

Scheiman M, Cotter S, Rouse M, Mitchell GL, Kulp M, Cooper J, Borsting E; Convergence Insufficiency Treatment Trial Study Group.
Br J Ophthalmol. 2005 Oct;89(10):1318-23.

Scheiman M, Mitchell GL, Cotter S, Kulp MT, Cooper J, Rouse M, Borsting E, London R, Wensveen J.
Optom Vis Sci. 2005 Jul;82(7):583-95.

Scheiman M, Mitchell GL, Cotter S, Cooper J, Kulp M, Rouse M, Borsting E, London R, Wensveen J; Convergence Insufficiency Treatment Trial Study Group.
Arch Ophthalmol. 2005 Jan;123(1):14-24.

Rouse MW, Borsting EJ, Mitchell GL, Scheiman M, Cotter SA, Cooper J, Kulp MT, London R, Wensveen J; Convergence Insufficiency Treatment Trial Group.
Ophthalmic Physiol Opt. 2004 Sep;24(5):384-90.

Borsting EJ, Rouse MW, Mitchell GL, Scheiman M, Cotter SA, Cooper J, Kulp MT, London R; Convergence Insufficiency Treatment Trial Group.
Optom Vis Sci. 2003 Dec;80(12):832-8.

Scheiman M, Gallaway M, Frantz KA, Peters RJ, Hatch S, Cuff M, Mitchell GL.
Optom Vis Sci. 2003 Mar;80(3):214-25.

21.
Gallaway M, Scheiman M, Malhotra K.
Optom Vis Sci. 2002 Apr;79(4):265-7.

Scheiman M, Cooper J, Mitchell GL, de LP, Cotter S, Borsting E, London R, Rouse M.
Optom Vis Sci. 2002 Mar;79(3):151-7.

Rouse MW, Borsting E, Hyman L, Hussein M, Cotter SA, Flynn M, Scheiman M, Gallaway M, De Land PN.
Optom Vis Sci. 1999 Sep;76(9):643-9.

Scheiman M, Blaskey P, Ciner EB, Gallaway M, Parisi M, Pollack K, Selznick R.
J Am Optom Assoc. 1990 Aug;61(8):600-5.

Gallaway M, Vaxmonsky T, Scheiman M.
J Am Optom Assoc. 1989 Jun;60(6):428-34.

Scheiman M, Gallaway M, Ciner E.
Am J Optom Physiol Opt. 1986 Jun;63(6):425-31. Review.

Scheiman MM, Peli E, Libassi D.
J Am Optom Assoc. 1983 Nov;54(11):1001-3. No abstract available.

No comments:

Post a Comment

You may comment on any aspect of this blog. You can not leave messages that promote or sell any service or product.